Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Decode Genetics Publishes the Largest Ever Study of the Plasma Proteome

REYKJAVIK, Iceland, Dec. 3, 2021 /PRNewswire/ -- In a study published today in Nature genetics, scientists at deCODE genetics , a subsidiary of the pharmaceutical company Amgen, demonstrate how measuring the levels of a large number of proteins in plasma at population scale when combined with dat...

2021-12-03 03:26 2641

Joint CUHK-HKU study discovers efficacy of COVID-19 vaccines correlates with a probiotic bacterium, Bifidobacterium adolescentis

HONG KONG, Dec. 2, 2021 /PRNewswire/ -- The Centre for Gut Microbiota Research of the Faculty of Medicine at TheChinese University of Hong Kong (CU Medicine) is among the first in the world to discover that germs in our gut (gut microbiota) modulate our immunity and disease severity in COVID-19. ...

2021-12-02 21:00 14478

Joint CUHK-HKU study discovers efficacy of COVID-19 vaccines correlates with a probiotic bacterium, Bifidobacterium adolescentis

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women - Results have already led to updated NCCN Guidelines® for breast cancer - New RxPONDER results to be fea...

2021-12-02 16:00 2481

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China

SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration ("NMPA") for marketing in main...

2021-12-02 08:00 2258

Sai Life Sciences' pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan

HYDERABAD, India, Dec. 1, 2021 /PRNewswire/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization (CRO/ CDMO), today announced that the Japanese regulatory...

2021-12-01 09:00 2195

Sai Life Sciences' pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan

Silexon Partners with Excelra, Deploying GOSTAR to Strengthen its AI-driven Drug Discovery and Biopharmaceutical Research Platform

HYDERABAD, India and NANJING, China, Dec. 1, 2021 /PRNewswire/ -- Excelra, a leading global data & analytics provider, today announced its partnership with Silexon AI Technology, a next-generation biotech company with a scalable AI/ML (Artificial Intelligence and Machine Learning) platform for dr...

2021-12-01 08:05 2241

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001

HANGZHOU, China, Dec. 1, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced the company has dosed the first patient with LNK01001 in its Phase II clinical trial in subjects with rheumatoid arthri...

2021-12-01 08:00 3163

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

SHANGHAI and CALGARY, Canada, Dec. 1, 2021 /PRNewswire/ -- Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant. Scientists from the two com...

2021-12-01 08:00 2113

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia

SUZHOU, China, SAN FRANCISCO and ROCKVILLE, Md., Dec. 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and...

2021-12-01 08:00 2338

EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

PROVIDENCE, R.I., Dec. 1, 2021 /PRNewswire/ -- Today EpiVax, Inc. ("EpiVax") confirmed that the company'sEPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. ("EVT") are also affirming commitment to move the novel T cell epito...

2021-12-01 05:22 1589

Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico's Proprietary End-to-end Artificial Intelligence Platform

NEW YORK and HONG KONG, Dec. 1, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company,today announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055.

2021-12-01 05:00 2326

Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico's Proprietary End-to-end Artificial Intelligence Platform

RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results

RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107's unique host-targeted mechanisms of action hold potential versus Omicron and other variants -- Phase 2/3 study s...

2021-11-30 22:30 3489

Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO

SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced today its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899, to HUYABIO Internation...

2021-11-30 20:42 2044

Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO

Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257

NEW YORK and HONG KONG, Nov. 30, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) applic...

2021-11-30 20:00 2245

Seegene's High Multiplex PCR Assay Capable of Detecting New Omicron Variant

SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today confirmed that its Allplex™ SARS-CoV-2 Master Assay is capable of detecting the Omicron's unique pattern of mutations. The well-established PCR-based test recogni...

2021-11-30 19:25 2134

JOYSBIO's SARS-COV-2 Antigen Rapid test detects OMICRON variant

TIANJIN, China, Nov. 30, 2021 /PRNewswire/ -- JOYSBIO, one of the world's leading manufacturers of lateral flow rapid tests, is proud to announce that their tests are available around the world. Furthermore, they've been able to show that their test can detect the new Omicron (B.1.1.529). This va...

2021-11-30 14:00 1939

Mayne Pharma and Mithra Announce TGA Approval of NEXTSTELLIS® Oral Contraceptive

ADELAIDE, Australia, Nov. 30, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of es...

2021-11-30 09:18 2346

Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease

HANGZHOU, China and SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today that it has signed a global, exclusive license agreemen...

2021-11-30 08:00 2761

Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board

HOUSTON and SINGAPORE, Nov. 29, 2021 /PRNewswire/ -- Hummingbird Bioscience Holdings Limited, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the appointment of Jan Møller Mikkels...

2021-11-29 17:00 1755

Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market

SHANGHAI and SAN DIEGO, Nov. 29, 2021 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze"), a clinical-stage pharmaceutical company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets, announced a$75 million Series A finan...

2021-11-29 10:00 3418

1 ... 95 96 979899 100 101 ... 181